23 July 2021
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.
Accrol Group Holdings plc
("Accrol" or the "Company")
Director Share Purchase
Accrol (AIM:ACRL), the UK's leading independent tissue convertor, announces that Dan Wright, Executive Chairman of Accrol, has today purchased 232,558 ordinary shares of £0.001 each ("Ordinary Shares") at a price of £0.43 per Ordinary Share.
Following this purchase, he now holds 11,515,5431 Ordinary Shares representing 3.61% of the current Issued Share Capital of the Company.
| 1 | 8,476,713 of these shares are registered in the name of Gomrath Limited, a family investment company controlled by Dan Wright |
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
|
| Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Dan Wright | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Chairman | ||||
| b)
| Initial notification /Amendment | Initial notification | ||||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Accrol Group Holdings plc | ||||
| b) | LEI | 213800MC56M5G69RJ226 | ||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a)
| Description of the financial instrument, type of instrument Identification code | Ordinary shares of £0.001 each
ISIN: GB00BZ6VT592 | ||||
| b) | Nature of the transaction | Purchase of Ordinary Shares | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Price |
| ||||
| e) | Date of the transaction | 23 July 2021 | ||||
| f) | Place of the transaction | London Stock Exchange, AIM | ||||
| For further information, please contact: |
|
|
|
|
| Accrol Group Holdings plc |
|
| Dan Wright, Executive Chairman | Via Belvedere Communications |
| Gareth Jenkins, Chief Executive Officer Richard Newman, Chief Financial Officer |
|
|
|
|
| Zeus Capital Limited (Nominated Adviser & Broker) |
|
| Dan Bate / Jordan Warburton | Tel: +44 (0) 161 831 1512 |
| Dominic King / John Goold | Tel: +44 (0) 203 829 5000 |
| | |
| Liberum Capital Limited (Joint Broker) | Tel: +44 (0) 20 3100 2222 |
| Clayton Bush / Edward Thomas | |
| | |
| Belvedere Communications Limited |
|
| Cat Valentine | Tel: +44 (0) 7715 769 078 |
| Keeley Clarke | Tel: +44 (0) 7967 816 525 |
| Llew Angus | Tel: +44 (0) 7407 023 147 |
| | accrolpr@belvederepr.com |
Overview of Accrol
Accrol Group Holdings plc is a leading tissue converter and supplier of toilet tissues, kitchen rolls, facial tissues, and wet wipes to many of the UK's leading discounters and grocery retailers across the UK. Following the recent acquisitions of LTC in Leicester and JD in Flint, North Wales, the Group now operates from six manufacturing sites, including four in Lancashire, which generate revenues totalling c.16% of the £2.1bn UK retail tissue market.
For more information, please visit www.accrol.co.uk
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
